- Home
- AUTL vs BNTC Comparison
AUTL vs BNTC Comparison
Compare AUTL & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | BNTC |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.6M | 365.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUTL | BNTC |
|---|---|---|
| Price | $1.55 | $13.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.33 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 3.9M | 276.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,128,000.00 | N/A |
| Revenue This Year | $658.11 | N/A |
| Revenue Next Year | $91.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 406.67 | N/A |
| 52 Week Low | $1.11 | $9.49 |
| 52 Week High | $3.11 | $17.15 |
Technical Indicators
Market Signals| Indicator | AUTL | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 51.20 |
| Support Level | $1.31 | $11.54 |
| Resistance Level | $1.61 | $13.17 |
| Average True Range (ATR) | 0.09 | 0.84 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 85.37 | 84.44 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.